A device for vaginal remodeling includes a preferably disposable, sterilizable handpiece which is an elliptical or preferably cylindrical applicator, adapted to be inserted in vagina. An electrode is positioned either on the outer surface of the handpiece or on the inner surface of the handpiece. A machine emits an RF sinusoidal signal, either continuous or pulsed, to cause heating in the tissues, or a plasma discharge, having a frequency from 10 kHz to 6 MHz, preferably between 50 kHz and 2 MHz, or between 200 kHz and 6 MHz, and connected to the electrode. Temperature sensors detect the temperature and are positioned on the handpiece. A PID algorithm is based software for feedback control of the power delivered on the basis of the detected temperature. The curvature radius of the electrode is equal to that of the handpiece on which it is positioned and is preferably tubular or annular.

A medical device is disclosed for monitoring and modulating uterine contractions. The medical device may include a uterine pacemaker and an intravaginal electrode carrier, which may both be located within the body. The intravaginal electrode carrier includes sensing and modulating electrodes that measure uterine electroactivity and apply electrical modulation, respectively. The uterine pacemaker receives the measured uterine electroactivity from the intravaginal electrode carrier and generates the electrical modulation applied by the modulating electrodes. The electrical modulation may be used to inhibit or induce uterine contractions. The intravaginal electrode carrier may be used in addition or as an alternative to an external uterine muscle activity monitor (e.g., a tocodynamometer) for a more accurate measure of uterine contractions that is noninvasive.

There is disclosed an apparatus for treating a sexual dysfunctional female patient, comprising an implanted stimulation device adapted to stimulate at least a part of the vagina of the patient by movement of said stimulation device and contact between said stimulation device and the sexually responsive tissue or the wall of the vagina. A system and an operation method for the treatment of female sexual dysfunction are also disclosed.

The systems and methods described herein generally relate to adjusting a neurostimulation (NS) therapy based on drug pharmacokinetics of a patient. The systems and methods deliver an NS therapy to a portion of electrodes of a lead positioned proximate to neural tissue of interest, which is associated with a target region. The NS therapy is defined by stimulation parameters. The systems and methods determine a trigger event indicative of a drug being administered to a patient. The drug is configured to affect at least one of the neural tissue of interest or the target region. The systems and methods adjust one or more of the stimulation parameters based on the PS profile.

The present disclosure relates to neural electrode technology for measuring a biosignal of a human or applying a neural signal to the human, and a neural electrode assembly includes a body that is inserted into a uterus in a non-invasive manner, a recording neural electrode formed to measure a uterine contraction-evoked neural signal, the recording neural electrode being coupled to the body, and a stimulating neural electrode formed to stimulate a nerve entering the uterus to suppress the uterine contraction, the stimulating neural electrode being coupled to the body.

The self-contained endocavitary probe device for managing stress incontinence is capable of being inserted into the vaginal or rectal cavity of a person. The device includes at least one self-contained electrical power supply so as to supply power to at least one device for measuring the variation in a parameter resulting from physical stress and to at least one electrical muscle stimulation device in contact with at least one muscle capable of maintaining urinary continence. The electrical stimulation device is activated in the event of variation in the parameter.

A device for providing fractional treatment of a body orifice includes a source of fractionated energy and a source of electrical muscle (EMS) energy. A programmed controller controls the application of fractionated and/or EMS energy. A probe is inserted by its distal end into the body orifice. The source of fractionated energy is positioned for transmitting fractionated energy from the source of fractionated energy through the probe to tissue in the vicinity around the body orifice; and, the source of EMS is positioned for transmitting EMS energy from the source of EMS energy through the probe to tissue in the vicinity around the body orifice. The programmed controller is configured to control the activation of fractionated energy and EMS energy one of simultaneously or sequentially.

Featured are intravaginal devices and methods of using the devices to observe the state of an individual's pelvic floor muscles in order to diagnose, treat, or prevent pelvic floor disorders (e.g., pelvic organ prolapse and incontinence) and their accompanying symptoms and methods of using the devices to treat or prevent vaginal disorders (e.g., skin laxity) in a subject using an energy transmitter (e.g., a radiofrequency transmitter).

The systems and methods described herein generally relate to adjusting a neurostimulation (NS) therapy based on drug pharmacokinetics of a patient. The systems and methods deliver an NS therapy to a portion of electrodes of a lead positioned proximate to neural tissue of interest, which is associated with a target region. The NS therapy is defined by stimulation parameters. The systems and methods determine a trigger event indicative of a drug being administered to a patient. The drug is configured to affect at least one of the neural tissue of interest or the target region. The systems and methods adjust one or more of the stimulation parameters based on the PS profile.

A system and method are provided for performing predictive permeation on the skin of a patient, particularly where the skin has no corneum. For this purpose, a device is provided which has an elongated probe, with an electrode array that extends along an active segment of the probe. Also, a voltage source is connected to the electrode array to generate an electric field. Operationally, an electro-conductive emulsion is applied onto the skin of the patient where the predictive permeation procedure is to be performed and the probe is positioned to contact the skin to be treated. The emulsion then interacts with the electric field that is generated by the electrode array to increase the permeability of the skin. Particles from a blood sample of the patient are included in the emulsion, and are introduced into the skin during the predictive permeation procedure to increase skin density.